Agios Pharmaceuticals announced that Stand Up To Cancer (SU2C), a charitable initiative for new cancer treatments, has selected the Cancer Metabolism 'dream team' led by Agios founder Dr Craig Thompson and including Agios advisors Dr Chi Dang and Dr Joshua Rabinowitz.

Cancer Metabolism is one of only five research areas chosen to share in $73.6 million in translational research funding, based on a rigorous selection process by independent scientific advisors assembled by SU2C's scientific partner, the American Association for Cancer Research (AACR).

Cancer metabolism is a new and exciting field of biology that represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth. This new understanding of a fundamental mechanism of cancer represents a powerful Achilles' heel to target this deadly disease.

With the help of Craig Thompson and other key advisors including Lewis Cantley and Tak Mak, Agios was founded a year ago to lead the translation of cancer metabolism biology and decades of metabolic biochemistry into novel cancer therapeutics that will make a difference for patients. In its first year of operation, Agios has taken a leadership position in the field of Cancer Metabolism with more than 40 employees and a rapidly emerging drug pipeline. Yesterday, Agios announced the appointment of its new leadership team to further lead and grow the vision of Agios. David Schenkein of Genentech will assume his role as chief executive officer in August and Duncan Higgons, formerly of Archemix, became the chief operating officer in May.

"It is great to see Stand Up To Cancer and AACR recognize and further validate the therapeutic potential of Cancer Metabolism which has been the driving vision behind building Agios over the past year," said David Schenkein, incoming chief executive officer of Agios Pharmaceuticals. "The progress to date of Agios has been impressive, bringing together great people, a passionate culture, deep science and an emerging pipeline of novel drugs that is leading the field rapidly downstream towards the clinic."

Stand Up To Cancer worked in collaboration with the American Association for Cancer Research (AACR) to identify and fund 'dream teams' in areas of cancer research that provide the most promising near term potential breakthrough therapies for patients. Cancer Metabolism was selected as one of the five research areas to receive SU2C research grants, based on the recommendation of a scientific advisory committee assembled by AACR.

Agios Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of cancer metabolism, which represents a breakthrough understanding of how cancer cells adapt to use more nutrients than normal cells to promote their survival and growth.